Korea’s Daewoong Pharma Inks $477 M Deal with US Partner for Autoimmune Disease Treatment

South Korea-based Daewoong Pharmaceutical has signed a Global License Agreement for its autoimmune disease drug candidate DWP213388 with Vitalli Bio, a US biotechnology company.